Article Text

Download PDFPDF

No primary association between LMP2 polymorphisms and extraspinal manifestations in spondyloarthropathies
  1. Thomas Höhlera,
  2. Thomas Schäpera,
  3. Peter M Schneiderb,
  4. Frank Krummenauerc,
  5. Christian Rittnerb,
  6. Karl-H Meyer zum Büschenfeldea,
  7. Elisabeth Märker-Hermanna
  1. aI Medical Department, bInstitute of Legal Medicine, cDepartment of Medical Statistics and Documentation, dJohannes Gutenberg University Mainz, Germany
  1. Dr T Höhler, I Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz, Langenbeckstr 1, 55101 Mainz, Germany.


OBJECTIVE To investigate the potential role of the HLA-linked LMP2 (low molecular weight protein) gene polymorphisms in conjunction with DR4 and DR7 on extraspinal disease manifestations in HLA-B27 positive patients with spondyloarthropathy.

METHODS 172 patients with spondyloarthropathy, 46 healthy, HLA-B27 positive blood donors, and 99 unrelated controls were typed for HLA-class I and II antigens. LMP2 alleles were determined by polymerase chain reaction and subsequent restriction enzyme digestion.

RESULTS There were statistically non-significant increases of DR4 and DR7 in spondyloarthropathy subjects. However these differences did not relate to specific extraspinal manifestations. There were no significant differences in the LMP2 genotype distribution in the disease groups. All differences in LMP2 genotype frequencies disappeared when correcting for DR4, which was in linkage disequilibrium with the LMP2B allele.

CONCLUSIONS There is no independent association between LMP2 genotypes and the occurrence of uveitis or peripheral arthritis in HLA-B27 positive subjects with spondyloarthropathy. DR4 and DR7 do not contribute to these disease manifestations.

  • LMP2 polymorphism
  • spondyloarthropathy
  • uveitis
  • peripheral arthritis

Statistics from

The seronegative spondyloarthropathies encompass a variety of disorders, which include reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel disease, undifferentiated spondyloarthropathy, a subgroup of juvenile chronic arthritis, and ankylosing spondylitis as a prototype of this group of related disorders.1 These disorders are linked together by common clinical, laboratory, and genetic factors. The most prominent genetic factor is the association with HLA-B27, which is found in 95% of patients with ankylosing spondylitis and with lower prevalence in the other spondyloarthropathies.1 Linkage of HLA-B27 and ankylosing spondylitis has been comprehensively shown in a large family study, which suggested that the disease is inherited in an autosomal dominant pattern with a low penetrance of 20%.2 It is still unclear, however, whether other genes inside the MHC contribute to the disease risk or influence the risk for extraspinal disease manifestations as peripheral arthritis or uveitis.

Transcomplementation has been shown for HLA-B60, which increases the risk for ankylosing spondylitis more than threefold in B27 positive people.3 The contribution of HLA-DR genes to extraspinal disease manifestations is controversial. One group has reported an increase of DR7 in patients with peripheral arthritis4 and DR8 seems to predispose to uveitis in Japanese patients.5A number of recent studies has focused on the association of MHC class II encoded TAP (transporter associated with antigen processing) and LMP (low molecular weight protein) genes, which participate in class I antigen processing.6-8

The LMP2 gene encodes a subunit of the proteasome, a cytoplasmic catalytic complex involved in the generation of antigenic peptides that are loaded on class I molecules within the endoplasmic reticulum.9

The LMP2 gene contains a coding polymorphism causing the exchange of arginine for histidine.6 Although nothing is known about the functional consequences of the LMP2 polymorphism, two recent studies reported an association of the LMP2 gene polymorphism with extraspinal disease in HLA-B27 positive subjects with ankylosing spondylitis.6 ,7 A third investigation could not confirm these findings.8 Unfortunately all three studies did not investigate the issue of linkage disequilibrium with class II antigens.

This study was done to test the hypothesis of an HLA-DR independent association between LMP2 genotypes and extraspinal manifestations in spondyloarthropathies. We did not find any such association. Deviations in LMP2 genotype frequencies could be explained by differences in HLA-DR frequencies and linkage disequilibrium between DR4 and LMP2B.



One hundred and seventy two HLA-B27 positive German white patients with seronegative spondyloarthropathy as defined by the European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy10 were included in this study. Fifty seven subjects (33%) were female, 115 subjects (67%) were male with a median age of 45.0 years (13–87). The median disease duration was 19.4 years (1–57). Reiter’s syndrome was present in two patients, reactive arthritis in seven patients, Crohn’s disease in six, and ulcerative colitis in one patient. Fifteen patients with psoriatic spondarthritis had been included in a previous study. All other patients (141 subjects) were suffering from ankylosing spondylitis. Forty seven patients (27.3%) had experienced at least one episode of uveitis. Peripheral arthritis had occurred in 74 patients (43%) during the disease course.

The control population consisted of 99 unrelated, healthy, German white persons from routine consecutive paternity cases investigated at the Institute of Legal Medicine11 and of 46 healthy German white HLA-B27 positive blood donors from Mainz. DNA was prepared from peripheral blood and stored at 4°C before use.


Analysis HLA-B27 was performed on peripheral blood lymphocytes by the standard microlymphocytotoxicity method.


Spondyloarthropathy patients were typed for DRB1*0401-11 and DRB1*0701, whereas control subjects were typed for DRB*0101 - DRB1*1601-02. DNA typing was done by nested polymerase chain reaction (PCR) amplification using sequence specific primers as described by Bein et al.12


PCR primers and conditions were as described previously.7 After PCR amplification samples were digested with HhaI (New England Biolabs) and alleles were assigned after electrophoresis on a 2.5 % agarose gel.


An extensive explorative statistical analysis was performed to detect possible differences in the proportion of LMP2BB versus LMP2AA/AB among several subgroups. Statistical analysis was done using the two sided exact Fisher test. Odds ratio and its 99% two sided confidence intervals are presented. The confidence levels were raised from the usual 95% to 99% because no adjustment for multiple comparisions was performed. The posteriori power π was calculated using the Casagrande/Pike/Smith approximation.13



For DR4 there was an increase of borderline significance in the spondyloarthropathy group compared with HLA-B27 controls (32%v 17.4%; p<0.07). DR4 frequencies were similar in all investigated spondyloarthropathy subgroups (30.6% in patients with peripheral arthritis and 34.8% in patients with uveitis). There was a non-significant increase for DR7 in the spondyloarthropathy group compared with B27 controls. A similar difference was observed when comparing DR7 frequencies in spondyloarthropathy patients with and without peripheral arthritis (15% v 25%, respectively; p<0.1).


Table 1 shows the data on LMP2 genotype frequencies in the different groups. We found no significant differences in the genotype distribution between healthy B27 controls and the entire spondyloarthropathy group. However, the LMP2BB genotype was enriched in DR4 positive patients with spondyloarthropathy (67.9%) compared with B27 positive, DR4 negative controls (44.4%; p<0,03; odds ratio 2.6) and with DR4 negative patients with spondyloarthropathy (50.4%; p<0.04; odds ratio 0.48) suggesting linkage disequilibrium of this allele to LMP2B. The non-significant enrichment of the BB genotype in patients with uveitis (60.9% v 47.8% in B27 positive controls) was almost equalised when DR4 positive subjects were removed from both groups (50.0% v 44.4% in B27 positive, DR4 negative controls). To exclude the introduction of a bias by choosing a heterogenous patient group encompasing a variety of disorders we analysed the ankylosing spondylitis patients separately. The LMP2BB genotype frequency in these patients matched almost exactly that in the entire spondyloarthropathy group (56.7% in ankylosing spondylitisv 55.8% in the spondyloarthropathy group). Neither subjects with peripheral joint involvement nor those with uveitis and peripheral arthritis showed any significant deviation in the LMP2 genotype distribution. LMP2A homozygotes were observed in all groups.

Table 1

LMP2 genotype distribution in the investigated groups. LMP2BB genotypes were compared against LMP2AB and AA genotypes. The significant differences in genotype distribution were between DR4 positive patients with spondyloarthropathy (SpA) compared with DR4 negative patients with SpA (1-150) and between DR4 positive patients with SpA compared with DR4 negative, B27 controls () (p < 0.03)


Our study shows that there is no independent association between the occurrence of uveitis and peripheral arthritis and the presence of the LMP2 BB genotype in HLA-B27 postive patients with seronegative spondyloarthropathy. Observed differences in LMP2BB genotypes are easily explained by the differences of DR4 frequencies in the investigated subgroups. After correction for DR4, the frequency of LMP2B homozygotes was similar in all spondyloarthropathy subgroups (51.9% in subjects with spondyloarthropathy without peripheral arthritis and uveitis; 50% in subjects with spondyloarthropathy and peripheral arthritis; 50% in subjects with spondyloarthropathy and uveitis).

Our investigation explains the controversial results of former studies on the association of LMP2B homozygosity with uveitis and peripheral arthritis in patients with seronegative spondyloarthropathies. None of these studies had controlled for DR genes. As shown in our study differences in the number of DR4 positive subjects can cause significant deviations of the LMP2B allele frequencies in disease subgroups. In this type of study it is particularly important to control for DR4 because more than 32% of HLA-B27 positive patients were DR4 positive. In contrast with other haplotypes that show a high recombination rate between the TAP1 and TAP2 genes DR4 bearing haplotypes seem to be more conserved.14 DR4 haplotypes show a particularly strong linkage disequilibrium to the DP genes encompasing the LMP2 gene, which lies telomeric to DP.14This explains the observed linkage disequilibrium between DR4 and the LMP2B allele that has been reported from other studies as well.15

There was a non-significant increase in the frequency of DR7 between patients with spondyloarthropathy with peripheral arthritis compared with those without peripheral joint disease. In a much smaller study Aaron et al 4 had reported an increase of DR7 in ankylosing spondylitis patients with peripheral joint disease. This association is probably a weak one and needs to be confirmed in a much larger study.


This work contains essential parts of the doctoral thesis of Thomas Schäper. We thank Dr Peter Hasenclever, Karl-Aschoff-Klinik Bad Kreuznach, for the excellent cooperation and the inclusion of numerous patients into our study.


Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.